Platelet rich plasma injections for osteoarthritis and other joint problems
Follows people with osteoarthritis after platelet rich plasma injections.
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Registry title
- Platelet Rich Plasma for Musculoskeletal Conditions
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 29 Dec 2025
- Expected to end
- 1 Jan 2035
- Type of study
- Interventional
- Treatments tested
- Platelet Rich Plasma Injection
- Platelet Rich Plasma Preparation
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a bone, joint, muscle or tendon problem who will get a platelet rich plasma (PRP) injection. They will be followed for one year.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- A musculoskeletal problem that a PRP injection may help, such as osteoarthritis of a joint, tendinopathy, epicondylitis or plantar fasciitis.
- Earlier treatment
- Other conservative (non-surgical) treatments must have failed.
Main reasons for not taking part
- Active cancer
- Active infection in the area of the injection
- A platelet disorder
- Active infection in the whole body
- Currently on dialysis
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 18+ years old
- Musculoskeletal pathology that may benefit from a PRP injection
- Failed other conservative treatments
Who cannot take part
- No active malignancy
- No active infection in the area of injection
- No active systemic infections
- No platelet disorder
- No patients currently undergoing dialysis
Where in United States
- University of Utah Orthoaedic CenterSalt Lake City, United StatesContact: Luke Johnson, BSTaking people
About the trial
What the trial wants to find out
The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction.
Read full original descriptionShow less
This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.
The group in the trial
- Platelet Rich Plasma InjectionTreatment being tested
Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their whole blood and the produced PRP will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months..
Treatment: Platelet Rich Plasma Injection and Platelet Rich Plasma Preparation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Platelet Rich Plasma for Musculoskeletal Conditions
- Plain-language title
- Platelet rich plasma injections for osteoarthritis and other joint problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 6 May 2026